Patent intelligence · EP
EP 1255725
5-AMINOLÄVULINSÄURE-FORMULIERUNG IN NICHTWÄSSRIGEN LÖSUNGSMITTELN
5-AMINOLÄVULINSÄURE-FORMULIERUNG IN NICHTWÄSSRIGEN LÖSUNGSMITTELN
Patent details — EP 1255725
- Jurisdiction
- EP
- Status
- expired
- Grant date
- Nov 13, 2002
- Expiration
- Nov 8, 2022
- Applicant
- ASAT AG APPLIED SCIENCE & TECH [CH]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 02 A I, A61K 9/ 06 A I, A61K 9/ 08 A I
Quick answer
EP 1255725 (5-AMINOLÄVULINSÄURE-FORMULIERUNG IN NICHTWÄSSRIGEN LÖSUNGSMITTELN) is held by ASAT AG APPLIED SCIENCE & TECH [CH]. Status: expired. Granted Nov 13, 2002. Expires Nov 8, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASAT AG APPLIED SCIENCE & TECH [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 02 A I, A61K 9/ 06 A I, A61K 9/ 08 A I, A61K 9/ 107 A I, A61K 31/ 197 A I
More from ASAT AG APPLIED SCIENCE & TECH [CH]
Related pharmaceutical patents in our USPTO index.
-
US 20260108463
NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION
granted -
US 2024335360
PRESSURIZED NANOEMULSION
granted -
WO 2024209065
NANOÉMULSION SOUS PRESSION
granted -
WO 2024209064
NANOÉMULSION SANS PROPYLÈNE GLYCOL
granted -
US 2024335380
NANOEMULSION WITHOUT PROPYLENE GLYCOL
granted -
US 2021315993
PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS
granted -
WO 2014117863
FORMES POLYMORPHES DE SELS D'ADDITION D'ACIDE DE THIOXANTHÈNE-9-YLIDÈNE-1-MÉTHYLPIPÉRIDINES UTILISÉS COMME COMPOSÉS ANTIMIGRAINEUX
granted -
DE 202010004750
Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
granted
Frequently asked questions
What is US patent 1255725?
EP 1255725 (5-AMINOLÄVULINSÄURE-FORMULIERUNG IN NICHTWÄSSRIGEN LÖSUNGSMITTELN) is held by ASAT AG APPLIED SCIENCE & TECH [CH]. Status: expired. Granted Nov 13, 2002. Expires Nov 8, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1255725?
ASAT AG APPLIED SCIENCE & TECH [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does EP 1255725 expire?
Our index shows an expiration date of Nov 8, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.